Myasthenia Gravis clinical trials at UCLA
1 research study open to eligible people
Showing trials for
Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
open to eligible people ages 18 years and up
A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.
Los Angeles, California and other locations
Our lead scientists for Myasthenia Gravis research studies include Perry B. Shieh, MD, PhD.
Last updated: